NNVC NANOVIRICIDES, INC.
Price Chart
Executive Summary
NanoViricides filed a universal shelf registration statement on Form S-3 to register up to $50 million in securities (common stock, preferred stock, debt, warrants, rights, units) for potential future sale. The company is a clinical-stage biotech with no revenue and an auditor's going-concern qualification, making this a likely capital-raising vehicle to fund Phase II trials and operations. The shelf represents a significant potential dilution risk relative to the $32M market cap.
Key Financial Metrics
Actionable Insight
Monitor for prospectus supplements indicating actual takedowns under the shelf. Any announced offering will likely be heavily dilutive given the micro-cap float. The going-concern qualification and zero-revenue profile suggest this is a distress-driven capital raise rather than opportunistic. Watch for ATM or registered direct offerings that could pressure the stock.
Key Facts
- Shelf registration of up to $50,000,000 in securities (common, preferred, debt, warrants, rights, units).
- Market cap is approximately $32M; the shelf size is ~156% of current market cap.
- Non-affiliate public float is approximately $35.5M (22.98M shares outstanding, ~626K held by affiliates, price $1.59).
- Company is a clinical-stage biotech with no customers, products, or revenues.
- Auditor's report includes an explanatory paragraph about substantial doubt regarding going concern.
- Proceeds intended for general corporate purposes including working capital and clinical trial funding.
- NV-387 is Phase II-ready; company is preparing MPox and Viral ARI/SARI trials.
- Facilities (18,000 sq ft) are owned free and clear of mortgage/debt.
Financial Impact
Potential dilution of up to ~156% of current market cap ($50M shelf vs $32M market cap). At the $1.59 reference price, full issuance would add ~31.4M shares, diluting existing holders by ~58%.
Risk Factors
- Massive potential dilution: $50M shelf is 156% of current $32M market cap.
- Going-concern qualification from auditor indicates high risk of capital exhaustion without this raise.
- Zero revenue and no approved products; clinical-stage risk with no guarantee of Phase II success.
- Stock price below $2.00 on NYSE American may trigger continued listing standards risk if it stays low.
- No specific use of proceeds beyond general corporate purposes — no catalyst tied to the filing.
Market Snapshot
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001104659-26-071007 |
| Document: tm2616485d1_ex-filingfees.htm | 0001104659-26-071007 |
| Document: tm2616485d1_ex5-1.htm | 0001104659-26-071007 |
| Document: tm2616485d1_ex23-2.htm | 0001104659-26-071007 |
| Document: 0001104659-26-071007-index-headers.html | 0001104659-26-071007 |
| Document: 0001104659-26-071007-index.html | 0001104659-26-071007 |
| Document: 0001104659-26-071007.txt | 0001104659-26-071007 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
7d ago
|
S-3
| $1.50 awaiting T+5 | awaiting T+5 | — | $1.22 (+18.67%) |
|
May 18, 2026
25d ago
|
424B5
| $1.51 $1.51 | · 0.00% | ▲ +1.62% | $1.22 (+19.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access